

Recurrent and Locally Advanced Rectal Cancer Surgery

20th Annual Conference of the Egyptian Group of Colon and Rectal Surgeons







Scott R. Steele, MD, MBA, FACS, FASCRS

Chairman, Department of Colorectal Surgery
Rupert B. Turnbull, M.D., Endowed Chair in Colorectal Surgery
Cleveland Clinic, Cleveland, OH
Professor of Surgery, CCLCOM

@ScottRSteeleMD



Case

■ 67 year-old female with prior anterior resection for rectosigmoid CA with recurrent pain and LBO





Questions to Ask

- Urgency of the situation?
- What was done surgically?
- Adjuvant therapy?
- Prior radiation?

- Anatomy of involvement
- Who do I need?
- Palliative or curative?
- Staged treatment?

Local Recurrence

- >5,000 patients/year in the USA
- If untreated:
 - median survival <12 months
 - Horrible complications
 - pelvic pain
- Most have exhausted other treatment options
- Many resectable at the time of diagnosis








Recurrent Rectal CA - Candidates

- Pre-TME
 - Local recurrence rates were 20-30%
 - Primarily due to inadequate mesorectal resection
- 5-17% of patients will develop recurrent rectal cancer (RRCA)
 - Despite TME
 - Despite adjuvant therapy
- Approximately 50% of patients are potential candidates for surgical resection
 - Only 30-40% will achieve an R0 resection
 - ~ 20% patients with recurrent rectal cancer are surgical candidates for cure
 Cleveland Clinic





Anterior and Posterior Margins






Anterior: the urogenital organs

Posterior: sacrum, piriformis, sacral plexus



Pelvic Patterns of Recurrence




Most located in the posterior part of the bony pelvis

Fewer than 5% involve the pelvic side wall

Sacrum & Coccyx involved in 30%

Advanced Pelvic Recurrence



What is a "Difficult Pelvic Dissection" in Recurrent Rectal Cancer?

- Distortion of anatomic planes
 - Inflammation
 - Scar tissue/adhesions
- Bleeding
- Injury to pelvic structures
 - Ureters
 - Bladder

- Multi-visceral involvement
- Local recurrence
 - After local excision
 - After radical excision





Strategic Planning

- Imaging
- Know what you are getting yourself into!
 - Team Building
 - Multidisciplinary surgical teams are better prepared
 - Intra/pre-operative
 - Neoadjuvant therapy
 - Stents
 - Reconstruction
 - Putting it back together





The Team

- Radiology
- Pathology/Blood
- GYN-Onc
- Urology
- Vascular Surgery
- Orthopedics
- Surgical Oncology

- Neurosurgery
- Plastic Surgery
- Radiation Oncology
- Anesthesia
- Colorectal Surgery
- Medicine / Impact





Planning Considerations

- 12% of rectal cancers extend beyond the mesorectum
- Postop chemoxrt
 doesn't prevent
 recurrence if
 circumferential margin
 is involved by tumor.
- R0 resection imperative


- Urinary System
- Male reproductive organs
- Female reproductive organs
- Small bowel
- Sacrum
- Pelvic side walls




Preoperative Evaluation

- Confirm the diagnosis
- Exclude distant metastasis
- Assess resectability
- Evaluate operative risk

Preoperative Staging = Proper Patient Selection









Limitations of Imaging Studies in Recurrent Rectal Cancer

- Most patients with recurrent rectal cancer received prior chemoradiation and/or prior surgery
- Preoperative images do not reliably predict postop pathology
 - Fibrosis vs tumor

- We still rely on imaging to help plan
 - Combining modalities may help mitigate the limitations of each one

MRI to Look for Local Invasion






Tumor Infiltrating Bladder Imaging Importance


CT Scan MRI








Upper Margin: Resectable Recurrence






Upper Margin: Unresectable Recurrence









Lateral Margins

Lateral: ureters, iliac vessels, side wall



Cleveland Clinic

Preoperative Considerations



■ Anatomic planes distorted from previous surgery

■ Distinction between scar and tumor almost impossible

 Anatomic planes opened at original operation potentially involved by recurrence



Operative Decisions

- Exclude intra-abdominal spread
- Assess resectability; if you think you can't remove the tumor, don't try
- Start dissection in planes that were normal on imaging



- Work around the tumor
- Avoid opening planes involved by tumor






En-bloc organs

■ Take fro

Identify



acent















Management of the Urinary System


- Extensive resections often requires complex reconstruction and permanent urinary diversion
- Urinary leaks common after chemoradiation
- Complete cystectomy or prostatectomy better
 results than partial resection
- Ureteral stents helpful






Pelvic Exenteration and Sacrectomy


Abdominal approach



Perineal approach




Perineal Dissection







Sacral View




Periosteal Elevation


Laminectomy


















Reported Outcomes

- 5-year survival
 - R0 resection: 37-60%
 - R1: 22%
 - R2: 10-14%
- Multimodality treatment
 - OS 31% vs. 24% in surgery alone
- Predictors of survival
 - R0 resection



- Multimodality treatment
- Neoadjuvant radiation





Author	Year	Number	R0 Resection	Morbidity (%)	Mortality (%)
Salo	1997	131	54	24	<1
Wanebo	1999	61	72	-	8
Garcia- Aguilar	2001	64	-	25	0
Hahnloser	2003	304	45	26	1
Moriya	2004	57	84	58	3
Vermass	2005	59 vs 33	64 vs 45	-	3 vs 0
Boyle	2005	64	37	35	2
Wiig	2006	150	44	46	<1
Maetani	2007	61	-	-	3
Heriot	2008	160	61	27	<1
Schurr	2008	72	51	15	9
Kusters	2009	170	54	-	7
You	2012	46	80	50	0
Bhangu	2014	100	78	53	0
Harris	2016	533	59	-	-
Tanaka	2017	180	74	66	1




Intra-operative Radiotherapy (IORT)


Indications

- Close R0 margins
- Known microscopically positive margins
- Grossly unresectable pelvic disease
- After sacrectomy











Intra-operative Radiotherapy (IORT)

- Controversial Data on efficacy
- Improved Local control
 - Compared to surgery alone
 - No clear effect on overall survival
 - Treiber 2004, Vermaas 2005, Hyngstrom 2014, Brady 2017
- Others: No difference in Local control or Survival
 - Wiig 2002, Tan 2013
- Most studies too underpowered to make definitive conclusions

Indication	Dose (cGy)
Minimal Residual Disease	1000
Gross residual Disease (R1 - <2cm)	1500
Gross residual Disease (R2, >2cm)	2000 Claveland Clini



Conclusion

- High morbidity
- Potentially curable
- Multidisciplinary team is critical
- Long-term survival in recurrent disease is possible if:
 - recurrence is truly isolated
 - diagnosed early
 - treated aggressively
 - resected with negative margins







Department of Colorectal Surgery Our Mission

To be leaders of Colorectal Surgery, rooted in our heritage, committed to the care of our patients, well-being of each other, and excellence in research, innovation, and education.



Cleveland Clinic

Every life deserves world class care.